New Leadership Team Set to Drive Growth and Innovation in Precision Medicine MedGenome, a leader in multiomics and precision medicine, has announced the appointment of Felix Olale, M.D., Ph.D., as President and Chief Executive Officer, and Jennifer Rose as Executive…
Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the closing of an oversubscribed $225 million Series B financing round. The syndicate wasled by General…
Catalent Affirms Commitment to Customers and Patients Amidst Novo Holdings Acquisition Alessandro Maselli to Remain President and CEO of Catalent Post-Acquisition Catalent, Inc. (NYSE: CTLT), a leader in the development and supply of innovative treatments for patients worldwide, has released…
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® in First-Line Treatment of Gastric, Gastroesophageal, and Esophageal Cancers BeiGene, a global oncology leader, has achieved a significant milestone with the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issuing…
Ferring Pharmaceuticals will present new research across four abstracts at the 2024 American Society for Reproductive Medicine (ASRM) Congress, taking place from October 19-23 in Denver, Colorado, and online. The abstracts include two oral and two poster presentations, reflecting Ferring’s…
Ferring Pharmaceuticals Showcases Commitment to Advancing Fertility Care at 2024 ASRM Congress Ferring Pharmaceuticals will present new data from four abstracts at the 2024 American Society for Reproductive Medicine (ASRM) Congress, taking place from October 19-23 in Denver, Colorado, and…
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) has announced that five of its abstracts have been accepted for e-Poster presentations at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI), scheduled to be held in Boston,…
Alnylam Pharmaceuticals, Inc. has submitted a Type II variation application to the European Medicines Agency (EMA) for vutrisiran, an investigational RNA interference (RNAi) therapy aimed at treating ATTR amyloidosis with cardiomyopathy (ATTR-CM). This application is based on the positive results…
Nordic Pharma Introduces LACRIFILL Canalicular Gel for Dry Eye at AAO 2024 Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., is showcasing LACRIFILL Canalicular Gel, a novel therapy for dry eye, at the American Academy of Ophthalmology (AAO) 2024.…
Charles River Laboratories International, Inc. (NYSE: CRL) has launched the Retrogenix® Non-Human Protein Library, a first-in-class in vitro tool designed to help biopharmaceutical clients assess off-target binding within a non-human proteome. This innovative library aims to de-risk in vivo studies…
Sage Therapeutics, Inc. (Nasdaq: SAGE) has unveiled a strategic reorganization initiative aimed at prioritizing the commercialization of ZURZUVAE® for postpartum depression while sharpening its focus on pipeline development, including the upcoming clinical study for dalzanemdor in Huntington’s Disease, slated for…
Artesunate AMIVAS, the first fully licensed treatment for severe malaria in Europe, is now available for purchase across Europe and the U.K. through Nordic Prime in Denmark. Approved by the European Commission and the U.K.’s Medicines and Healthcare products Regulatory…